Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib in Resected EGFR-Mutated NSCLC
NCT06227897Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Jun 2024; status: withdrawn.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06227897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06227897.